Similar findings were obtained from an obese related pediatric Italian NAFLD population, demonstrating the involvement of the PNPLA3 in regulating the response to this pharmacologic intervention (36). This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.